Where every popular peptide stands with the FDA.
Where every popular peptide stands with the FDA right now: approved, under review, or not permitted, with the next milestone for each.
Understand what is known about risk, and what regulatory language actually means.
8 articles in this collection
Where every popular peptide stands with the FDA right now: approved, under review, or not permitted, with the next milestone for each.
BPC-157 isn't FDA-approved and can't legally be compounded yet, despite a July 2026 advisory vote in its favor. Here's what changed and what hasn't.
TB-500 isn't FDA-approved and can't be legally compounded yet. Here's how a 2026 advisory vote changed its outlook, and what still stands in the way.
An FDA advisory panel voted to recommend six peptides for compounding, overruling the agency's own scientists. Here's what the vote did, and what it didn't.
The FDA's category system decides which peptides pharmacies can compound while the official list is pending. Here's how Categories 1, 2, and 3 work.
Online peptide sellers lean on "research use only" and "not for human consumption." The FDA says those labels don't make a product legal, and they tell you something important about quality.
A dated record of the FDA's crackdown on online peptide sellers: who received warning letters, what the agency cited, and what has escalated beyond letters.
What small BPC-157 reports and FDA safety information can—and cannot—tell us about risk, product quality and long-term uncertainty.
Try a compound name, like BPC-157, or a broader word, like safety.
All articles are AI-assisted editorial content checked against cited sources.